February 13, 2025
TOPLINE: Cabozantinib improves progression-free survival (PFS) in patients with advanced extrapancreatic neuroendocrine tumors and pancreatic neuroendocrine tumors compared with placebo. METHODOLOGY: Cabozantinib, an oral small-molecule inhibitor […]